Drachman Jonathan G, Senter Peter D
1Seattle Genetics Inc, Bothell, WA.
Hematology Am Soc Hematol Educ Program. 2013;2013:306-10. doi: 10.1182/asheducation-2013.1.306.
For more than a century, the concept of a "magic bullet" to deliver cytotoxic therapy to the site of disease has been envisioned but only recently have technological advances enabled antibody-drug conjugates to fulfill that dream. The recent approvals of brentuximab vedotin and ado-trastuzumab emtansine and emerging data for many molecules in clinical trials highlight the potential for antibody-drug conjugates to offer new therapeutic options for patients. This chapter reviews the evolution, state of the art, and potential future improvements that are enabling rapid development of this important class of cancer therapeutics.
一个多世纪以来，人们一直设想能有一种“神奇子弹”将细胞毒性疗法送达疾病部位，但直到最近，技术进步才使抗体药物偶联物能够实现这一梦想。近期，brentuximab vedotin和ado曲妥珠单抗（ado-trastuzumab emtansine）的获批以及众多分子在临床试验中的新数据，都凸显了抗体药物偶联物为患者提供新治疗选择的潜力。本章回顾了这一重要癌症治疗药物快速发展所经历的演变、现状及未来可能的改进。
